Kamile Ozturk1, Ferit Avcu, A Ugur Ural. 1. Aksaray University, Faculty of Science and Letters, Molecular Biology Department, Aksaray, Turkey. kamileztrk@yahoo.com.tr
Abstract
BACKGROUND: Leptin and adiponectin receptors mediate the role of leptin in stimulating the growth of leukemic cells and the protective function of adiponectin undertaken in several malignancies such as leukemia. In this study, we investigated the involvement of the expression of leptin and adiponectin receptors in chronic myeloid leukemia (CML) pathogenesis. METHODS: The expression of leptin receptor isoforms, OB-Rt, OB-Ra, and OB-Rb, and the expression of adiponectin receptors, AdipoR1 and AdipoR2, were measured as mRNA levels in two CML cell lines (K562 and Meg-01) and 20 CML patients and 24 healthy controls by using RT-PCR. RESULTS: OB-Rt and OB-Ra isoforms expression of the leptin receptors were found to be significantly lower in Meg-01 cell lines than K562 cells. All leptin receptors were downregulated in CML patients and more particularly OB-Rb level was found to be undetectably low in normal PBMC as well as in CML patients. AdipoR1 expression level was higher in Meg-01 than in K562, whereas AdipoR2 level was found to be unchanged in both cell lines. Interestingly, while AdipoR1 expression increased in CML patients, AdipoR2 decreased. Moreover, imatinib therapy did not affect both leptin and adiponectin isoform expressions. CONCLUSION: While the decrease in leptin receptor levels in CML patients was confirmed, the increase in AdipoR1 levels and relevant decrease in AdipoR2 levels depicted their possible involvement in CML pathogenesis. This suggests different functions of adiponectin receptors in CML development.
BACKGROUND:Leptin and adiponectin receptors mediate the role of leptin in stimulating the growth of leukemic cells and the protective function of adiponectin undertaken in several malignancies such as leukemia. In this study, we investigated the involvement of the expression of leptin and adiponectin receptors in chronic myeloid leukemia (CML) pathogenesis. METHODS: The expression of leptin receptor isoforms, OB-Rt, OB-Ra, and OB-Rb, and the expression of adiponectin receptors, AdipoR1 and AdipoR2, were measured as mRNA levels in two CML cell lines (K562 and Meg-01) and 20 CMLpatients and 24 healthy controls by using RT-PCR. RESULTS:OB-Rt and OB-Ra isoforms expression of the leptin receptors were found to be significantly lower in Meg-01 cell lines than K562 cells. All leptin receptors were downregulated in CMLpatients and more particularly OB-Rb level was found to be undetectably low in normal PBMC as well as in CMLpatients. AdipoR1 expression level was higher in Meg-01 than in K562, whereas AdipoR2 level was found to be unchanged in both cell lines. Interestingly, while AdipoR1 expression increased in CMLpatients, AdipoR2 decreased. Moreover, imatinib therapy did not affect both leptin and adiponectin isoform expressions. CONCLUSION: While the decrease in leptin receptor levels in CMLpatients was confirmed, the increase in AdipoR1 levels and relevant decrease in AdipoR2 levels depicted their possible involvement in CML pathogenesis. This suggests different functions of adiponectin receptors in CML development.
Authors: Thao Trinh; James Ropa; Arafat Aljoufi; Scott Cooper; Anthony Sinn; Edward F Srour; Hal E Broxmeyer Journal: Leukemia Date: 2020-11-07 Impact factor: 11.528
Authors: Laszlo Otvos; Daniel Knappe; Ralf Hoffmann; Ilona Kovalszky; Julia Olah; Tim D Hewitson; Roma Stawikowska; Maciej Stawikowski; Predrag Cudic; Feng Lin; John D Wade; Eva Surmacz; Sandor Lovas Journal: Front Chem Date: 2014-10-17 Impact factor: 5.221
Authors: Niklas Landberg; Sofia von Palffy; Maria Askmyr; Henrik Lilljebjörn; Carl Sandén; Marianne Rissler; Satu Mustjoki; Henrik Hjorth-Hansen; Johan Richter; Helena Ågerstam; Marcus Järås; Thoas Fioretos Journal: Haematologica Date: 2017-12-28 Impact factor: 9.941
Authors: Hemant Kulkarni; Harald H H Göring; Vincent Diego; Shelley Cole; Ken R Walder; Greg R Collier; John Blangero; Melanie A Carless Journal: BMC Med Genomics Date: 2012-08-23 Impact factor: 3.063